Didier Branellec appointed Non-Executive Director

Eco Animal Health Group PLC

08 September 2026

 

8 September 2026

ECO Animal Health Group plc

("ECO" or the "Company")

Didier Branellec appointed as Independent Non-Executive Director

ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces the appointment of Dr. Didier Branellec as an Independent Non-Executive Director of the Company, effective immediately.

Didier is a senior life sciences executive bringing over two decades of international corporate strategy and business development experience across biotechnology, pharmaceuticals, animal and human health. Didier is currently Senior Vice President, Business Alliances at BioNTech, where he leads global partnerships with pharmaceutical and biotechnology companies and academic institutions and oversees major alliance-related transactions. In addition, Didier has also served as a Strategic Advisor to Archimed, a global healthcare investment firm, to identify investment opportunities in animal health.

Prior to BioNTech, Didier worked at Boehringer Ingelheim, as Vice President, Global Strategy, Business Development & Digital, Animal Health, where he developed the Animal Health business unit strategy and was a member of its executive committee. He was subsequently appointed Vice President, Corporate Strategy & Development, with focus on animal health, human pharmaceuticals and biopharmaceutical contract manufacturing.

Didier also spent 15 years at Merial, a leading global animal health company operated as a division of Sanofi, where he held a series of increasingly senior roles, including Vice President and Global Head of Business Development. As a member of the Merial executive leadership team, he successfully executed more than 50 transactions, including in-licensing, commercial and M&A, and played a senior role in the asset swap that saw Merial become part of Boehringer Ingelheim.

David Hallas, Chief Executive Officer of ECO Animal Health, commented: "We are delighted to welcome Didier to the Board as an Independent Non-Executive Director. His international career, extensive network and strong track record of strategic execution and successful transactions in animal health and beyond will offer invaluable insights that are well aligned to ECO's growth plans."

Didier Branellec, Independent Non-Executive Director of ECO Animal Health, added: "ECO Animal Health is strongly positioned to deliver its next phase of growth, driven by the launch of new self-developed innovative products, new market penetration and in-licensing opportunities. With over two decades of experience in the animal health sector, I look forward to working closely with the ECO Board to ensure we capitalise on the significant opportunities ahead."

In accordance with Schedule 2(g) of the AIM Rules for Companies, Didier Branellec (aged 60) has not held any directorships or partnerships in the past five years. 

As at the date of this announcement, Didier holds no shares nor any other beneficial interest in the Company.

There is no further information about Didier required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

-Ends-

Contacts

ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)	020 8447 8899
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson Phillip Marriage	020 3709 5700
Singer Capital Markets (Nominated Adviser & Joint Broker) Jen Boorer Sara Hale James Fischer	020 7496 3000
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden	020 3100 2000
Equity Development Hannah Crowe Matt Evans	020 7065 2692

About ECO Animal Health

ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.

The Group's proprietary lead product, Aivlosin^® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.

ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO's pipeline, ECOVAXXIN^® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in July 2026.

Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.

View the Group's website or LinkedIn page for further information.

 

END